NEW YORK, Jan. 27 /PRNewswire-FirstCall/ -- Pfizer Inc said today that Exubera (inhaled human insulin powder) has been approved by the European Commission but has not yet been approved by the U.S. Food and Drug Administration. The company expects that the FDA will issue a decision concerning Exubera shortly. Pfizer regrets an incorrect statement it made to CNBC about the regulatory status of Exubera in the U.S. and is correcting it with CNBC. Information about the approval of Exubera by the European Commission is available at http://www.pfizer.com.
Source: Pfizer Inc
